DRW Securities’s ImmunityBio IBRX Stock Holding History

DRW Securities’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-11,139	Closed	-$85.4K	–	1194
2026 Q1	$85.4K	Sell	11,139 -53,033	-83%	-$363K	﹤0.01%	1192
2025 Q4	$127K	Sell	64,172 -78,216	-55%	-$177K	﹤0.01%	1034
2025 Q3	$349K	Buy	+142,388	New	+$367K	0.01%	777

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

DRW Securities's IBRX Position: Q2 2026 in Review

DRW Securities sold out of ImmunityBio (IBRX) in Q2 2026, closing a stake of 11,139 shares — an estimated $85.4K sold.

DRW Securities first reported a position in IBRX in Q3 2025 and held it in 3 quarters. The position peaked at $349K in Q3 2025. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

DRW Securities reported no remaining ImmunityBio position as of Q2 2026 after selling out during the quarter.
DRW Securities sold 11,139 ImmunityBio shares in Q2 2026, an estimated $85.4K.
DRW Securities first reported a position in ImmunityBio in Q3 2025 and held it in 3 quarters.
DRW Securities's ImmunityBio position peaked at $349K in Q3 2025.
405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on DRW Securities's 13F filing for Q2 2026, filed 14 Aug 2026.